For the year ending 2025-12-31, RARE has $1,532M in assets. $1,605M in debts. $421M in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 421 | |||
| Marketable securities | 259 | |||
| Accounts receivable, net | 158 | |||
| Inventory | 52 | |||
| Prepaid expenses and other assets | 61 | |||
| Total current assets | 951 | |||
| Property, plant and equipment, gross | 380 | |||
| Less accumulated depreciation | 136 | |||
| Property, plant, and equipment, net | 244 | |||
| Marketable securities | 57 | |||
| Intangible assets, net | 176 | |||
| Goodwill | 44 | |||
| Other assets | 60 | |||
| Total assets | 1,532 | |||
| Accounts payable | 31 | |||
| Accrued liabilities | 265 | |||
| Lease liabilities | 12 | |||
| Liabilities for sales of future royalties | 69 | |||
| Other liabilities | 7 | |||
| Total current liabilities | 384 | |||
| Lease liabilities | 24 | |||
| Deferred tax liabilities | 30 | |||
| Liabilities for sales of future royalties | 1,147 | |||
| Other liabilities | 20 | |||
| Total liabilities | 1,605 | |||
| Noncontrolling interest | 7 | |||
| Treasury stock, at cost, 0.2 shares in 2025 and 0.1 shares in 2024 | 8 | |||
| Deferred compensation obligation | 8 | |||
| Additional paid-in capital | 4,451 | |||
| Accumulated other comprehensive income (loss) | 1 | |||
| Accumulated deficit | -4,532 | |||
| Total stockholders' equity (deficit) | -80 | |||
| Total liabilities, noncontrolling interest and stockholders' equity (deficit) | 1,532 | |||
Ultragenyx Pharmaceutical Inc. (RARE)
Ultragenyx Pharmaceutical Inc. (RARE)